Clinical Trials Sponsored by MSD International GmbH (Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.)

Total 60 results

ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

A Study of ARQ 171 in Patients With Advanced Solid Tumors

Cancer

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, Italy
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Solid Tumor

United States, Italy
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

An Extension Study for Patients Previously Treated With ARQ 501

Cancer

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Pancreatic Neoplasms

Poland
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Phase 2 Study in Patients With MiT Tumors

Renal Cell Carcinoma (RCC) | Alveolar Soft Part Sarcoma (ASPS) | Clear Cell Sarcoma (CCS)

United States, Canada, United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers

Healthy

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype

Healthy

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

No longer available

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

Growth Disorders | Proteus Syndrome | PIK3CA-Related Overgrowth Spectrum (PROS)
ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Ovarian Cancer | Endometrial Cancer | Solid Tumors

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Solid Tumor | Tumor | Malignant Lymphoma

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Mixed Hepatocellular Cholangiocarcinoma

United States, Italy
ArQule, Inc. (a wholly owned subsidiary of Merck...

Withdrawn

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

Gastric Cancer
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

Unresectable Hepatocellular Carcinoma

Belgium, Italy, United States, Germany, Canada
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors (ARQ 197)

Cancer, Advanced Solid Tumors

United Kingdom
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

Cancer

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma

Cancer

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer

Adenocarcinoma | Pancreatic Cancer

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

Cancer | Solid Tumors

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Advanced Solid Tumors
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Metastatic Non-Small Cell Lung Cancer

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Poland, Germany, Russian Federation, Latvia, Ukraine
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Cirrhosis

Spain, United States, Italy
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

ARQ 197 in Subjects With Metastatic Solid Tumors

Cancer | Tumor

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

ARQ 501 in Subjects With Cancer

Cancer

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

ARQ 501 in Combination With Docetaxel in Patients With Cancer

Carcinoma

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (SPECTRA)

Pulmonary Arterial Hypertension

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

Charcot-Marie-Tooth Disease | Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women

Osteoporosis

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth Disease

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Phase 1 Study of ACE-083 in Healthy Subjects

Musculoskeletal Diseases

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Anemia

Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia

B-Thalassemia

Italy, Greece
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 in Healthy Postmenopausal Women

Anemia

United States
ArQule, Inc., a subsidiary of Merck Sharp & Dohme...

Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Lymphoma, B-Cell | Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Richter's Transformation

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR)

Pulmonary Arterial Hypertension

Spain, United States, Israel, Australia, Germany, United Kingdom, France, Brazil
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Beta Thalassemia

Beta-Thalassemia

Greece, Italy
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

ACE-536 Extension Study - Myelodysplastic Syndromes

Myelodysplastic Syndromes

Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Study of ACE-2494 in Healthy Subjects

Healthy Volunteers

Canada

Clinical Trials Sponsored by MSD International GmbH (Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations